ONeil Trader
Latest Articles
Amarin: Addressing The Mineral Oil Issue
Amarin: More Room To Run After REDUCE-IT Success
Ra Pharmaceuticals: Is Trying To Copy What Works A Good Product Development Strategy?
Heron Therapeutics: Update After HTX-011 Nerve Block Results
Baozun Continues To Execute
Supernus Keeps Delivering
Learning From The Best - How Joseph Edelman (Perceptive Advisors) Invests
The Investment Case For InflaRx
NovoCure: 2018 Off To A Strong Start For Optune
Heron Therapeutics: Clear Path To Approval For HTX-011
ChemoCentryx: Significant Progress In Recent Months
More Positive Developments For Neurocrine
TG Therapeutics: The Most Important Catalyst Coming In Q2
LGI Homes: Growth To Slow Down In 2018
Amicus Therapeutics: What To Expect In 2018
Neos Therapeutics: Cotempla Off To A Strong Start
Omeros: OMS721 Updates Are Very Positive, But Where's The Update On Omidria?
Biotech: The Tide Is Turning
Global Blood Therapeutics: The Significance Of ASH Updates
Horizon Pharma: Primary Care Segment Remains A Burden And Should Be Sold
The Investment Case For Ascendis Pharma
Selecta Biosciences: SEL-212 Phase 2 Data Not As Good As Hoped, But The Potential Is Still There
RedHill Biopharma: When Good News Means Nothing
Flexion Therapeutics: Zilretta Approved, Now What?
Omeros: One Overhang Removed, One Remaining
A Lost Year For OPKO Health
Supernus: Market Overreacts After Interim Analysis Of SPN-810 Phase 3 Trial
BioDelivery Sciences: Change Is Good?
LGI Homes: Still Well Positioned To Grow
Baozun: More Room To Run?
Neos Therapeutics: Focusing On Execution
Lexicon Pharmaceuticals: Stock Out Of Favor But Fundamentals Improving